PUBLISHER: IMARC | PRODUCT CODE: 1675361
PUBLISHER: IMARC | PRODUCT CODE: 1675361
The global viscosupplementation market size reached USD 4.8 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 9.1 Billion by 2033, exhibiting a growth rate (CAGR) of 7.05% during 2025-2033. The increasing prevalence of osteoporosis and osteoarthritis (OA) and the shifting consumer inclination toward minimally invasive non-surgical treatments represent some of the key factors driving the market.
Viscosupplementation represents a minimally invasive medical procedure wherein intraarticular injection comprising gel-like fluid known as exogenous hydraulic acid (HA) derivatives are directly administered into the knee joints of the patient. It acts as a lubricant, which enables bones to move smoothly over each other, lowers inflammation, and performs as a shock absorber for joint loads. Viscosupplementation reduces the friction during the movements, assists the synovial fluids in creating more cushion, eliminates severe pain, and enhances the range of movements or motions of the joint. Apart from this, it restores the rheological properties of the synovial fluids, which produce mechanical, analgesic, anti-inflammatory, and chondroprotective effects. As a result, viscosupplementation is extensively utilized in the treatment of knee, hip, and hand osteoarthritis. Currently, it is mainly available in intermediate, low, and high molecular weights.
The increasing prevalence of osteoporosis and osteoarthritis (OA) represents one of the key factors driving the market growth. In line with this, the shifting consumer inclination toward the minimally invasive non-surgical treatment options has facilitated the widespread adoption of viscosupplementation in the healthcare sector for corticosteroids and joint pain management. This, in turn, is acting as another major growth-inducing factor. This is further influenced by the growing consumer awareness regarding the multiple benefits of non-surgical treatments, including no hospitalization, fewer expenses, minimal complications, and better clinical outcomes and recovery rates. Additionally, the favorable government initiatives and significant investments by various pharmaceutical companies to launch novel drugs and different routes of administrations is supporting the market growth. Moreover, the emergence of ambulatory surgical centers (ACS) that offer intensive treatment to resolve surgical and non-surgical problems in various body parts, such as joints, ligaments, muscle, spine, and nerves, is favoring the market growth. Furthermore, the introduction of open-label single-injections with hydraulic acid is propelling the market growth. Apart from this, favorable health insurance reimbursement policies, the rising geriatric population, which is susceptible to chronic ailments, increasing number of individuals with chronic disability, collaborations and partnership among the key players, and continuous research and development (R&D) activities in the field of medical sciences are positively impacting the market growth.
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.